06 August 2018
Little Green Pharma have sponsored a new digital platform, GreenChoices to provide both medical practitioners and patients with meaningful research and education, with the aim of assisting them make informed choices about medical cannabis as a possible treatment option.
Our team wish to support the demand for education and research around this new treatment so have developed and procured educational content from independent medical professionals for the GreenChoices website.
Because an informed choice will make for a better treatment decision and outcome!
It is currently difficult to access comprehensive information about medicinal cannabis and associated medical research. An increasing number of Australians are:
- interested in finding out more about medical cannabis, or
- wanting to access medical cannabis (via their doctor).
However, there is lack of clear information on medicinal cannabis and how to access this treatment via the Special Access Scheme or clinical trials.
Plenty of useful and unbiassed content
GreenChoices is committed to providing comprehensive information on this site, including:
1) Education & clarification
For patients & doctors to better understand medical cannabis, research and the process to access this new pharmaceutical medication in Australia.
Specially designed questionnaires with the objective of assisting patients or learning more about patient experiences using cannabinoid therapy.
3) Resources & Education for doctors – Coming soon!
A restricted access portal for Healthcare Professionals – detailed information about applications, the legal framework, available products, dosing information, educations and courses.
4) Clinical trials – Coming soon!
A list of all the current clinical trials into medicinal cannabis that are currently being offered in Australia. As well as the ability for doctors to register their interest for trial participation.
Sign up to the GreenChoices newsletter and social media pages to stay up-to-date with news and changes in the industry, including accessibility to medicinal cannabis and services for patients.Back to news